CN Mobile Logo

Search form


Support Program for Melanoma Patients Receiving Interferon

Support Program for Melanoma Patients Receiving Interferon

NEW YORK--Cancer Care, Inc. has introduced Crossing Bridges, a national program to provide medically accurate information and ongoing emotional support to malignant melanoma patients receiving adjuvant therapy with interferon alfa-2b (Intron A).

The program, made possible by a grant from Schering-Plough Corporation, is designed to encourage treatment compliance by providing diverse support services during the entire treatment period

"The side effects during Intron A therapy can be significant, particularly at the beginning," said John Kirkwood, MD, of the University of Pittsburgh Cancer Institute. "I call it 'a flu in a bottle'; ie, headaches, fever, nausea, and loss of appetite."

These symptoms and the year-long treatment can be emotionally challenging. "Someone will be there to guide patients every step of the way," said Diane Blum, executive director of Cancer Care.

Patients will receive a journal to log thoughts and questions, and chart therapy milestones; a list of support services and recommended readings; one-on-one counseling and support groups through Cancer Care (1-800-813-HOPE); a monthly phone call from a nurse counselor; and information about the Buddy Program, which pairs a current patient with someone who has successfully completed treatment.

Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.